Allogene Therapeutics, Inc. (ALLO) CEO David Chang on Q1 2022 Results - Earnings Call Transcript [Seeking Alpha]
Allogene Therapeutics, Inc. (ALLO)
Last allogene therapeutics, inc. earnings: 2/27 04:30 am
Check Earnings Report
Company Research
Source: Seeking Alpha
Allogene Therapeutics, Inc. (NASDAQ:ALLOCompany ParticipantsChristine Cassiano - Chief Communications OfficerDavid Chang - President and Chief Executive OfficerRafael Amado - EVP of Research and Development and Chief Medical OfficerEric Schmidt - Chief Financial OfficerConference Call ParticipantsTyler Van Buren - CowenCory Kasimov - JP MorganSalveen Richter - Goldman SachsJohn Newman - CanaccordLuca Issi - RBC CapitalKalpit Patel - B. RileyAnand Sankar - TruistRaju Prasad - William BlairDane Leone - Raymond JamesOperatorThank you for standing by, and Welcome to Allogene Therapeutics First Quarter 2022 Conference Call [Operator Instructions].I would now like to turn the call over to Christine Cassiano, Chief Communications Officer. Please go ahead.Thank you, operator, and welcome to all who have joined this call. After the market closed today, Allogene issued a press release that provides a business update and financial results for the first quarter of 2022. This press release and tod
Show less
Read more
Impact Snapshot
Event Time:
ALLO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ALLO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ALLO alerts
High impacting Allogene Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
ALLO
News
- Allogene Therapeutics, Inc. (NASDAQ: ALLO) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $10.00 price target on the stock.MarketBeat
- Allogene Therapeutics, Inc. (NASDAQ: ALLO) had its "outperform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $10.00 price target on the stock.MarketBeat
- Allogene Therapeutics, Inc. (NASDAQ:ALLO) Q4 2023 Earnings Call Transcript [Yahoo! Finance]Yahoo! Finance
- Allogene's (ALLO) Q4 Loss Narrower Than Expected, Sales Miss [Yahoo! Finance]Yahoo! Finance
- Allogene Therapeutics (ALLO) Reports Q4 Loss, Lags Revenue Estimates [Yahoo! Finance]Yahoo! Finance
ALLO
Earnings
- 3/14/24 - Miss
ALLO
Sec Filings
- 3/18/24 - Form 4
- 3/14/24 - Form S-8
- 3/14/24 - Form S-3
- ALLO's page on the SEC website